Frontier Pharma-Schizophrenia-Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms

Schizophrenia is a chronic mental disorder that affects 1% of the population-equivalent to 51 million people worldwide-and is ranked among the top 10 causes of disability in developed countries. It is a debilitating condition that affects those afflicted, their families and society as a whole.

In 2013, the direct and indirect cost of schizophrenia to US society was estimated to be $155 billion. Despite this, the schizophrenia pipeline is relatively small. This is indicative of a low level of R&D funding and investment in schizophrenia, most likely due to a poor understanding of the underlying mechanisms of the disease, which hinders the development of effective pharmaceutical drugs.

Request Sample Copy @https://www.premiummarketinsights.com/sample/GBI00004596     

There are marketed pharmaceutical products that are effective in treating the positive symptoms of schizophrenia, but none are available for the treatment of negative and cognitive symptoms. There is no single pharmacological drug that addresses all the symptoms of schizophrenia, and therefore it is likely that in the future combined treatments based on pharmacogenetics will be used to provide a tailored approach.

As such there is a strong rationale for continued R&D investment in schizophrenia therapeutics, due to the high levels of unmet need across a large population. This report assesses first-in-class innovation across the schizophrenia pipeline.

Request for Discount @ https://www.premiummarketinsights.com/discount/GBI00004596      

Table of Contents:

1 Table of Contents 2

2 Executive Summary 5

3 The Case for Innovation 6

4 Clinical and Commercial Landscape 10

5 Assessment of Pipeline Product Innovation 20

6 Schizophrenia Pathophysiology and Innovation Alignment 30

7 First-in-Class Molecular Target Evaluation 33

8 Deals and Strategic Consolidations 47

9 Appendix 57

Purchase Complete Report https://www.premiummarketinsights.com/buy/GBI00004596

Contact Info:
Name: Sameer Joshi
Email: [email protected]
Organization: Premium Market Insights
Phone: +1-646-491-9876

 

About Premium Market Insights:

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider

Posted by on Monday May 20 2019, 5:45 AM EDT. All trademarks acknowledged. Filed under Business & Financial Services, Business Services, Featured Press Release, Healthcare, Life Sciences, Pharmaceuticals. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Latest News

Log in